R-salbutamol ( DrugBank: Salbutamol, R-salbutamol )


1 disease
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus2

49. Systemic lupus erythematosus


Clinical trials : 946 Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004635-29-DK
(EUCTR)
09/11/200702/10/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate
Astion Pharma A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Denmark;Spain;Sweden
2EUCTR2007-004635-29-SE
(EUCTR)
07/11/200712/09/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate
Astion Pharma A/SNULLNot RecruitingFemale: yes
Male: yes
140Denmark;Spain;Sweden